EQL Pharma (EQL) Panoramica del titolo
EQL Pharma AB (publ) si occupa dello sviluppo, della commercializzazione e della vendita di farmaci generici a farmacie e ospedali in Svezia, Danimarca, Norvegia, Finlandia e nel resto d'Europa. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 6/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
EQL Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
SEK 86.37
FV
72.4% sottovalutato sconto intrinseco21.49%
Revenue growth p.a.
156
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
Concorrenti di EQL Pharma AB (publ)
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | SEK 23.85 |
| Massimo di 52 settimane | SEK 98.60 |
| Minimo di 52 settimane | SEK 21.35 |
| Beta | 0.25 |
| Variazione di 1 mese | -3.05% |
| Variazione a 3 mesi | -56.64% |
| Variazione di 1 anno | -73.82% |
| Variazione a 3 anni | -14.82% |
| Variazione a 5 anni | -32.05% |
| Variazione dall'IPO | 311.21% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 17
EQL: European Rollout And New UTI Therapy Will Drive Future Upside
Analysts have kept their SEK price target for EQL Pharma broadly unchanged, with only minimal adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E. This reflects a largely steady view of the stock's valuation profile.Aggiornamento della narrazione • Jun 02
EQL: European Rollout And Supply Chain Improvements Will Drive Future Upside
Analysts have reduced their fair value estimate for EQL Pharma’s shares from SEK 75 to SEK 50, citing updates to their models that reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News EQL Pharma issued earnings guidance for 2026/27, with sales growth below its long term 30% target and an EBITDA margin of 10%, reflecting impacts from supply shortages and one off effects.Articolo di analisi • May 14
This Analyst Just Downgraded Their EQL Pharma AB (publ) (STO:EQL) EPS Forecasts
The analyst covering EQL Pharma AB (publ) ( STO:EQL ) delivered a dose of negativity to shareholders today, by making a...Articolo di analisi • May 13
EQL Pharma AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
There's been a major selloff in EQL Pharma AB (publ) ( STO:EQL ) shares in the week since it released its yearly...Recent updates
Aggiornamento della narrazione • Jun 17
EQL: European Rollout And New UTI Therapy Will Drive Future Upside
Analysts have kept their SEK price target for EQL Pharma broadly unchanged, with only minimal adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E. This reflects a largely steady view of the stock's valuation profile.Aggiornamento della narrazione • Jun 02
EQL: European Rollout And Supply Chain Improvements Will Drive Future Upside
Analysts have reduced their fair value estimate for EQL Pharma’s shares from SEK 75 to SEK 50, citing updates to their models that reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News EQL Pharma issued earnings guidance for 2026/27, with sales growth below its long term 30% target and an EBITDA margin of 10%, reflecting impacts from supply shortages and one off effects.Articolo di analisi • May 14
This Analyst Just Downgraded Their EQL Pharma AB (publ) (STO:EQL) EPS Forecasts
The analyst covering EQL Pharma AB (publ) ( STO:EQL ) delivered a dose of negativity to shareholders today, by making a...Articolo di analisi • May 13
EQL Pharma AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
There's been a major selloff in EQL Pharma AB (publ) ( STO:EQL ) shares in the week since it released its yearly...Aggiornamento della narrazione • Apr 23
EQL: Italian Approval And New Market Entry Will Support Future Upside Potential
Analysts have adjusted their price target on EQL Pharma to SEK 75 from SEK 80, citing updated assumptions for revenue growth, profit margins and future P/E. These changes point to a slightly more conservative outlook on the shares.Aggiornamento della narrazione • Apr 09
EQL: Italian Market Entry And Steady Assumptions Will Support Future Upside Potential
Analysts have maintained their SEK price target for EQL Pharma at SEK 80.00, citing consistent assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News EQL's key product Mellozzan, which contains melatonin, has received Marketing Authorization approval from the Italian medicines agency AIFA for use in Italy, through licensing partner Italfarmaco S.p.A. (Key Developments) Mellozzan is indicated for children with ADHD who have sleep difficulties where sleep hygiene measures have not worked, and for short term treatment of jet lag in adults.Aggiornamento della narrazione • Mar 26
EQL: Long Term Incentive Program Will Support Strong Future Upside Potential
Analysts keep their SEK 80.00 fair value estimate for EQL Pharma unchanged, reflecting steady assumptions on discount rate, revenue growth, profit margin and future P/E, with no new Street research prompting a shift in the target. What's in the News A special or extraordinary shareholders meeting is scheduled for February 3, 2026, at 13:00 W.Aggiornamento della narrazione • Mar 11
EQL: Long Term Incentive Program Will Support Strong Future Upside Potential
Analysts have kept their price target for EQL Pharma steady at SEK 80. This reflects unchanged views on fair value, discount rate, growth and margin assumptions.Aggiornamento della narrazione • Feb 24
EQL: Leadership Restructuring And Incentive Plan Will Support Long Term Outlook
Analysts have kept their SEK price target for EQL Pharma unchanged at SEK 80. This reflects stable assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E.Aggiornamento della narrazione • Feb 10
EQL: German UTI Prophylaxis Approval Will Support Stronger Long Term Outlook
Analysts have kept their fair value estimate for EQL Pharma unchanged at SEK 80.00. They explain the steady target by slightly different views on discount rate, revenue growth, profit margin and future P/E assumptions rather than any single strong new data point.Aggiornamento della narrazione • Jan 27
EQL: German UTI Prophylaxis Launch Will Support Bullish Outlook
Analysts have kept their fair value estimate for EQL Pharma unchanged at SEK 80.00 per share, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E. What's in the News EQL Pharma has called a special or extraordinary shareholders meeting for February 3, 2026, at 13:00 W.Aggiornamento della narrazione • Jan 12
EQL: Future UTI Prophylaxis Launch In Germany Will Drive Upside
Analysts have maintained their price target on EQL Pharma at SEK 80.00, citing consistent assumptions for the discount rate, revenue growth, profit margin and future P/E that support keeping the previous fair value assessment unchanged. What's in the News EQL Pharma has called a special/extraordinary shareholders meeting for February 3, 2026, at 13:00 W.Aggiornamento della narrazione • Dec 23
EQL: Future UTI Prophylaxis Launch Will Drive Strong Upside Potential
Analysts have modestly adjusted their price target on EQL Pharma upward to SEK 80.0 per share from SEK 80.0 per share, citing unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples that continue to support the company’s current fair value assessment. What's in the News EQL Pharma strengthens and reorganizes its finance function, appointing Allan Sylvest Aasberg as new CFO from early April 2026, while current CFO Anna Jönsson becomes Head of Accounting (Key Developments) The new CFO is tasked with optimizing profitability, capital allocation, forecasting, and parts of investor relations to support a more scalable growth platform (Key Developments) Key product methenamine hippurate receives marketing approval in Germany under the EQL brand Cystohipp, the only registered product of its kind in that market, with launch planned for mid 2026 (Key Developments) Cystohipp targets recurrent urinary tract infections as a non antibiotic prophylactic option, addressing growing demand for alternatives that do not drive antibiotic resistance (Key Developments) EQL issues guidance indicating robust top line expansion, forecasting around 30 percent sales growth for 2024/25 and around 15 percent for 2025/26 (Key Developments) Valuation Changes Fair Value: unchanged at SEK 80.0 per share, indicating no revision to the overall equity valuation.Aggiornamento della narrazione • Dec 09
EQL: New Non-Antibiotic UTI Therapy Will Drive Future Upside
Narrative Update on EQL Pharma Analysts have maintained their price target for EQL Pharma at SEK 80.00. This reflects unchanged assumptions on revenue growth, profitability, and valuation multiples despite recent model refinements.Aggiornamento della narrazione • Nov 25
EQL: Expanding Market Approvals And New Launches Will Drive Future Upside
Analysts have maintained their price target for EQL Pharma at SEK 80.00. They cite stable fair value estimates supported by slightly improved projections for revenue growth and profit margin.Articolo di analisi • Nov 15
EQL Pharma's (STO:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Last week's earnings announcement from EQL Pharma AB (publ) ( STO:EQL ) was disappointing to investors, with a sluggish...Aggiornamento della narrazione • Nov 06
EQL: Expansion Into New Markets Will Drive Upside In Coming Years
Analysts have lowered their price target for EQL Pharma from SEK 90.00 to SEK 80.00. They cite revised expectations for valuation and a slightly higher discount rate, despite improved forecasts for revenue growth and profit margin.Articolo di analisi • Oct 08
EQL Pharma AB (publ) (STO:EQL) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
EQL Pharma AB (publ) ( STO:EQL ) shareholders that were waiting for something to happen have been dealt a blow with a...Articolo di analisi • Sep 27
Do EQL Pharma's (STO:EQL) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Articolo di analisi • Sep 09
Capital Allocation Trends At EQL Pharma (STO:EQL) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
Aggiornamento della narrazione • Aug 16
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
2025 Q2 update Solid report. Revenue growth in line with expectations.Articolo di analisi • May 16
EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality
EQL Pharma AB (publ) ( STO:EQL ) just reported some strong earnings, and the market reacted accordingly with a healthy...Nuova narrazione • May 11
Pipeline Launches And Global Expansion Will Drive Future Success
Strategic expansions and acquisitions, including Medilink and non-European market entry, are poised to drive significant revenue and profitability growth.Articolo di analisi • Mar 12
Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Nuova narrazione • Feb 22
EQL Pharma aiming for 19% Revenue Growth in 5 Years
Recurring Cash Flow: EQL’s core generic product delivers near‐“infinite” cash flow, thanks to its essential role in healthcare.Articolo di analisi • Jan 27
The Trend Of High Returns At EQL Pharma (STO:EQL) Has Us Very Interested
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Articolo di analisi • Dec 14
EQL Pharma AB (publ)'s (STO:EQL) P/E Is Still On The Mark Following 37% Share Price Bounce
Despite an already strong run, EQL Pharma AB (publ) ( STO:EQL ) shares have been powering on, with a gain of 37% in the...Articolo di analisi • Nov 27
Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Articolo di analisi • Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher
The EQL Pharma AB (publ) ( STO:EQL ) share price has done very well over the last month, posting an excellent gain of...Articolo di analisi • Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
EQL Pharma AB (publ)'s ( STO:EQL ) stock showed strength, with investors undeterred by its weak earnings report. We...Articolo di analisi • Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
The EQL Pharma AB (publ) ( NGM:EQL ) share price has done very well over the last month, posting an excellent gain of...Articolo di analisi • May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Articolo di analisi • Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
EQL Pharma AB (publ)'s ( NGM:EQL ) recent weak earnings report didn't cause a big stock movement. Our analysis suggests...Rendimenti per gli azionisti
| EQL | SE Healthcare | SE Mercato | |
|---|---|---|---|
| 7D | 1.1% | 8.2% | 3.4% |
| 1Y | -73.8% | -0.6% | 13.2% |
Ritorno vs Industria: EQL ha avuto una performance inferiore rispetto al Swedish Healthcare che ha registrato un rendimento -0.6 % nell'ultimo anno.
Rendimento vs Mercato: EQL ha avuto una performance inferiore al mercato Swedish che ha registrato un rendimento 13.2 % nell'ultimo anno.
Volatilità dei prezzi
| EQL volatility | |
|---|---|
| EQL Average Weekly Movement | 13.6% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.4% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di EQL è stato volatile rispetto al mercato Swedish.
Volatilità nel tempo: La volatilità settimanale ( 14% ) di EQL è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni Swedish.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2006 | 60 | Axel Schorling | www.eqlpharma.com |
EQL Pharma AB (publ) si occupa dello sviluppo, della commercializzazione e della vendita di farmaci generici a farmacie e ospedali in Svezia, Danimarca, Norvegia, Finlandia e nel resto d'Europa. Offre prodotti iniettabili per cure ospedaliere e formulazioni per cure ambulatoriali. EQL Pharma AB (publ) è stata costituita nel 2006 e ha sede a Lund, in Svezia.
EQL Pharma AB (publ) Riepilogo dei fondamenti
| EQL statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | SEK 704.28m |
| Utili (TTM) | SEK 12.54m |
| Ricavi(TTM) | SEK 432.66m |
56.2x
Rapporto P/E1.6x
Rapporto P/SEQL è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| EQL Conto economico (TTM) | |
|---|---|
| Ricavi | SEK 432.66m |
| Costo del fatturato | SEK 269.82m |
| Profitto lordo | SEK 162.84m |
| Altre spese | SEK 150.30m |
| Utili | SEK 12.54m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 0.42 |
| Margine lordo | 37.64% |
| Margine di profitto netto | 2.90% |
| Rapporto debito/patrimonio netto | 167.9% |
Come si è comportato EQL nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/05 20:36 |
| Prezzo dell'azione a fine giornata | 2026/07/03 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
EQL Pharma AB (publ) è coperta da 1 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Erik Hultgård | DNB Carnegie Commissioned Research |